Hypertension and paroxysmal atrial fibrillation: A novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence

Journal of Human Hypertension

Volumn 24, Issue 7, 2010, Pages 447-457

  Rizos, I ^a   Rigopoulos, A G ^a   Kalogeropoulos, A S ^a   Tsiodras, S ^a   Dragomanovits, S ^a   Sakadakis, E A ^a   Faviou, E ^a   Kremastinos, D T ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

atrial fibrillation; C reactive protein; cardioversion; interleukins; recurrence

Indexed keywords

ACENOCOUMAROL; AMIODARONE; C REACTIVE PROTEIN; ENOXAPARIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AUTACOID; BIOLOGICAL MARKER;

AGED; ANTICOAGULATION; ARTICLE; CARDIOVERSION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAROXYSMAL HEART ATRIUM FIBRILLATION; PREDICTOR VARIABLE; RECURRENT DISEASE; SINUS RHYTHM; THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLOOD; CASE CONTROL STUDY; COMPLICATION; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ELECTRIC COUNTERSHOCK; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953810398     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.89     Document Type: Article

References (39)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-2375.
2. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26(20): 2083-2092.
3. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27(2): 136-149.
4. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104(24): 2886-2891.
5. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108(24): 3006-3010.
6. Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, Murali NS et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005; 46(7): 1284-1287.
7. Wazni O, Martin DO, Marrouche NF, Shaaraoui M, Chung MK, Almahameed S et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005; 91(10): 1303-1305.
8. Cosgrave J, Foley JB, Bahadur K, Bennett K, Crean P, Walsh MJ. Inflammatory markers are not associated with outcomes following elective external cardioversion. Int J Cardiol 2006; 110(3): 373-377.
9. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-Reactive protein in lone atrial fibrillation. Am J Cardiol 2006; 97(9): 1346-1350.
10. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001; 56(6): 375-380.
11. Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004; 45(3): 441-445.
12. Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J 2000; 21(20): 1653-1665.
13. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38(4): 1231-1266.
14. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 2003; 41(6): 1036-1043.
15. Wang Y, Gutman JM, Heilbron D, Wahr D, Schiller NB. Atrial volume in a normal adult population by twodimensional echocardiography. Chest 1984; 86(4): 595-601.
16. Sookoian S, Castano G, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 2009; 42(7-8): 624-629.
17. Rizos I, Tsiodras S, Rigopoulos AG, Dragomanovits S, Kalogeropoulos AS, Papathanasiou S et al. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine 2007; 40(3): 157-164.
18. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41(2): 255-262.
19. Dernellis J, Panaretou M. Relationship between Creactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25(13): 1100-1107.
20. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003; 91(6A): 15D-26D.
21. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004; 94(4): 508-510.
22. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108(3): 346-353.
23. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008; 94(2): 200-204.
24. Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 2005; 59(8): 881-885.
25. Aguiar-Souto P, Toquero-Ramos J, Fernandez-Lozano I. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006; 29(12): 1452.
26. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49(15): 1642-1648.
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6): 448-454.
28. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96(10): 3542-3548.
29. Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996; 77(3): 10A-23A.
30. Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogorb F et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24(14): 1373-1380.
31. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274(3 Pt 2): R577-R595.
32. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103(5): 769-777.
33. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92(7): 1954-1968.
34. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86(12): 1259-1265.
35. Sarkar S, Vellaichamy E, Young D, Sen S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol 2004; 287(1): H107-H117.
36. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999; 42(1): 162-172.
37. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K et al. C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005; 20(2): 45-49.
38. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95(6): 764-767.
39. Wasmund SL, Li JM, Page RL, Joglar JA, Kowal RC, Smith ML et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 2003; 107(15): 2011-2015.